Literature DB >> 26228967

Therapeutic effect of atropine 1% in children with low myopia.

Shu Yi1, Yuanshuai Huang2, Shi-Zhi Yu1, Xi-Jia Chen1, Hong Yi1, Xiao-Li Zeng3.   

Abstract

PURPOSE: To evaluate the efficacy of topical atropine 1% in promoting unaided visual acuity, reducing myopia, and slowing the progression of ocular axial elongation in Chinese children with low myopia.
METHODS: Children with low myopia were randomly assigned to one of two groups, receiving either atropine 1% (treatment group) or placebo eyedrops (control group) once nightly for 1 year. After instillation of 3 drops of cyclopentolate 1%, unaided visual acuity, cycloplegic refraction, and ocular axial length were tested and recorded at baseline (2 weeks after atropine or vehicle eyedrops), 3 months, 6 months, 9 months, and 1 year.
RESULTS: A total of 132 children 7-12 years of age with a refractive error of spherical equivalent -0.50 D to -2.00 were included. After 1 year, the mean unaided visual acuity in the treatment group was 0.31 ± 0.16 logMAR; in the control group, 0.66 ± 0.15 logMAR, (P < 0.0001). After treatment for 1 year, there was a decrease of 0.32 ± 0.22 D from baseline in the treatment group and an increase of -0.85 ± 0.31 D in the control group (P < 0.0001). The axial elongation in the treatment group was -0.03 ± 0.07 mm; in the control group, 0.32 ± 0.15 mm (P < 0.0001).
CONCLUSIONS: In this study cohort, topical atropine1% reduced the degree of low myopia and slowed the progression of ocular axial elongation in children.
Copyright © 2015 American Association for Pediatric Ophthalmology and Strabismus. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26228967     DOI: 10.1016/j.jaapos.2015.04.006

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  16 in total

Review 1.  Efficacy and Adverse Effects of Atropine in Childhood Myopia: A Meta-analysis.

Authors:  Qianwen Gong; Miroslaw Janowski; Mi Luo; Hong Wei; Bingjie Chen; Guoyuan Yang; Longqian Liu
Journal:  JAMA Ophthalmol       Date:  2017-06-01       Impact factor: 7.389

Review 2.  Myopia: Mechanisms and Strategies to Slow Down Its Progression.

Authors:  Andrea Russo; Alessandro Boldini; Davide Romano; Giuseppina Mazza; Stefano Bignotti; Francesco Morescalchi; Francesco Semeraro
Journal:  J Ophthalmol       Date:  2022-06-14       Impact factor: 1.974

Review 3.  [Current recommendations for deceleration of myopia progression].

Authors:  W A Lagrèze; L Joachimsen; F Schaeffel
Journal:  Ophthalmologe       Date:  2017-01       Impact factor: 1.059

4.  Axial length targets for myopia control.

Authors:  Paul Chamberlain; Percy Lazon de la Jara; Baskar Arumugam; Mark A Bullimore
Journal:  Ophthalmic Physiol Opt       Date:  2021-05-05       Impact factor: 3.117

5.  Interventions to slow progression of myopia in children.

Authors:  Jeffrey J Walline; Kristina B Lindsley; S Swaroop Vedula; Susan A Cotter; Donald O Mutti; Sueko M Ng; J Daniel Twelker
Journal:  Cochrane Database Syst Rev       Date:  2020-01-13

6.  Atropine 0.5% eyedrops for the treatment of children with low myopia: A randomized controlled trial.

Authors:  Yan-Rong Wang; Hong-Li Bian; Qi Wang
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

7.  Low-Concentration Atropine Eye Drops for Myopia Progression.

Authors:  Fen Fen Li; Jason C Yam
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2019 Sep-Oct

Review 8.  Which low-dose atropine for myopia control?

Authors:  Safal Khanal; John R Phillips
Journal:  Clin Exp Optom       Date:  2019-09-05       Impact factor: 2.742

Review 9.  Pathogenesis and Prevention of Worsening Axial Elongation in Pathological Myopia.

Authors:  Sangeethabalasri Pugazhendhi; Balamurali Ambati; Allan A Hunter
Journal:  Clin Ophthalmol       Date:  2020-03-18

10.  Effects of Atropine Treatment on Choroidal Thickness in Myopic Children.

Authors:  Luyao Ye; Ya Shi; Yao Yin; Shanshan Li; Jiangnan He; Jianfeng Zhu; Xun Xu
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-12-01       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.